1,139 results on '"He, Qiaojun"'
Search Results
102. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends
103. Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment
104. PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications
105. The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets
106. Corrigendum to “Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics” [Eur. J. Pharmacol. 926 (2022) 175035]
107. A Practical 'Pretacs-Cytoblot' Platform Accelerates the Streamlined Development of Protac-Based Protein Degraders
108. Potential of Compounds Originating from the Nature to Act in Hepatocellular Carcinoma Therapy by Targeting the Tumor Immunosuppressive Microenvironment: A Review
109. Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress
110. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation
111. A novel gene fusion RUNX1/ZNF423promotes leukemic relapse of NUP98-rearranged AML
112. SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
113. Genetic dominance of transforming growth factor-β1 polymorphisms in chronic liver disease
114. PROTAC-DB 2.0: an updated database of PROTACs
115. Regorafenib inhibits EphA2 phosphorylation damages the liver via ERK/MDM2/p53 axis
116. IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model
117. The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma
118. Deubiquitinating enzymes: Promising targets for drug resistance
119. 5-Fluorouracil causes severe CNS demyelination by disruption of TCF7L2/HDAC1/HDAC2 complex in adolescent mice
120. Targeting Labile Iron-Mediated Ferroptosis on Renal Proximal Tubular Epithelial Cells Provides a Potential Therapeutic Strategy for Rhabdomyolysis-Induced Acute Kidney Injury
121. Identification and Validation of Two Heterogeneous Molecular Subtypes and a Prognosis Predictive Model for Hepatocellular Carcinoma Based on Pyroptosis
122. SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ
123. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs
124. Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics
125. The Role of Membrane-Associated E3 Ubiquitin Ligases in Cancer
126. Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer
127. Nutlin-3 inhibits epithelial–mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis
128. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis
129. Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization
130. The Selectivity and Potency of the New PDE5 Inhibitor TPN729MA
131. Structures of the endogenous peptide- and selective non-peptide agonist-bound SSTR2 signaling complexes
132. Progress and perspective of organoid technology in cancer-related translational medicine
133. JAK-STAT signaling as an ARDS therapeutic target: status and future trends
134. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
135. Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression
136. Targeted Protein Degradation and Regulation with Molecular Glue: Past and Recent Discoveries
137. Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells
138. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors
139. The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies
140. Reduced HMGB1 expression contributed to lapatinib-induced cutaneous injury
141. WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit
142. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
143. Additional file 2 of CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
144. PROTAC-DB 2.0: an updated database of PROTACs.
145. Potential of Compounds Originating from the Nature to Act in Hepatocellular Carcinoma Therapy by Targeting the Tumor Immunosuppressive Microenvironment: A Review.
146. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc
147. Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors
148. New Insights of CCR7 Signaling in Dendritic Cell Migration and Inflammatory Diseases
149. Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma
150. Deneddylation of PML/RARα reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.